Mesothelioma Survival Rate

Less than half of people diagnosed with mesothelioma survive more than a year, less than 10 percent survive more than three years.

Key Points about Mesothelioma Survival Rate

  • Location, stage, and cell type of mesothelioma as well as overall patient health, have the greatest impact on survival rate.
  • The survival rate for mesothelioma patients is improving in part because of improvements in treatment options.

What is Survival Rate and How Long Will I Live With Mesothelioma?

Mesothelioma survival rate is a measurement (usually expressed as a percentage) of the amount of patients who survive a given amount of time after diagnosis. Survival rates are a way for doctors to talk to patients about their overall prognosis, or disease outlook. It helps inform patients about how aggressive or treatable the disease is known to be. Because there are a number of factors that impact survival, it’s difficult to answer with any kind of certainty how long a mesothelioma patient will live.

If a patient wishes to know how their specific circumstances impact their survival, their doctor may give them a life expectancy estimate, or how long the patient may live following their individual diagnosis.

Mesothelioma Survival Rates

  • Patients who live 1 year or more  //  30-40 percent
  • Patients who live 2 years or more // 15-20 percent
  • Patients who live 5 years or more // 5-10 percent

New Emerging Treatments can Improve Mesothelioma Life Expectancy

Factors that Impact Mesothelioma Survival Rate

Type of Mesothelioma

The location where mesothelioma originates can impact a patient’s chances of survival. Pleural and peritoneal are the two most common types of mesothelioma, and recent studies show that the survival rates of these types of mesothelioma are improving thanks in part to advancements in treatment. A 2015 study found the following survival rates for these types of mesothelioma:

1 year5 years10 years
Pleural73 percent12 percent4.7 percent
Peritoneal91.6 percent65.3 percent39.4 percent

Cell Type

Of the three major malignant mesothelioma subtypes — epithelioid, sarcomatoid, and biphasic — epithelioid mesothelioma tends to progress more slowly and is much more likely to respond to cancer treatment, while sarcomatoid is the most aggressive of the three. Prognosis for biphasic patients usually falls somewhere between the other two types, but as the percentage of sarcomatoid cells increases, the duration of survival decreases.

Median Survival Times for Patients By Cell Type

19 mo
13 mo
8 mo

Stage of Mesothelioma

The stage of mesothelioma at the time of a diagnosis is heavily factored into determining a patient’s likelihood of long term survival. It is important to note that pleural mesothelioma is the only type with an official staging system. Patients with early stage mesothelioma who respond well to treatment have the best survival rates while late stage mesothelioma is usually treated palliatively given the increasingly limited treatment options.Stage

Unfortunately, mesothelioma is most often diagnosed in the later stages given the long latency period and delayed onset of symptoms, which mimic more common illnesses.

Median Survival Time by Stage

  • Stage I:  21 months
  • Stage II: 19 months
  • Stage III: 16 months
  • Stage IV: 12 months

There are also a number of patient-specific circumstances that impact a patient’s chances of survival, including their age, sex, and genetics.

Patient Factors


Older mesothelioma patients generally have poorer survival rates because they cannot tolerate aggressive treatments as well as younger patients, and are often managing other chronic conditions.


Studies show that women with pleural mesothelioma appear to have better survival rates than men. For instance, 13.4% of women with pleural mesothelioma survived at least 5 years, compared to 4.5% of male patients with similar characteristics. This may be because men, who account for 80% of all mesothelioma cases, are predominantly exposed during industry-related work, while women are often exposed secondhand by spouses, family, or friends who bring asbestos dust back home on clothing. Research is still being done to determine why there is such a discrepancy despite age, cancer stage, race, or treatment.


There have been some studies that show certain genetic factors play a role in how long mesothelioma patients survive after diagnosis. One example is patients who carry mutated BRCA1-associated protein-1 (BAP1) have better survival rates.

Impact of Treatment on Survival Rate

A patient’s chances of survival depend greatly on their treatment options and the effectiveness of the treatment. For patients who are able to tolerate surgery that successfully removes the tumor, survival rates tend to be higher.

Significant improvements in survival have also been seen in patients who undergo multimodal therapy, or therapy that combines surgery with other treatments like chemotherapy and radiation. For example, peritoneal mesothelioma patients have a significantly better survival rate, thanks in large part to advancements in treatment options for peritoneal mesothelioma, namely hyperthermic intraperitoneal chemotherapy (HIPEC), which combines cytoreductive surgery and heated chemotherapy.


Send Me a Free Guide Guide Photo

1 Where should we overnight your free guide?

2 Recipient information.

    Sources & About the Writer [+]
    • 1 Ai, J. and J. P. Stevenson (2014). "Current issues in malignant pleural mesothelioma evaluation and management." Oncologist 19(9): 975-984.
    • 2 Balduyck, B., et al. (2010). "Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?" Ann Thorac Surg 89(3): 907-911.
    • 3 Berk, S., et al. (2012). "Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years' experience in Turkey." Asian Pac J Cancer Prev 13(11): 5735-5739.
    • 4 Bovolato, P., et al. (2014). "Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients." J Thorac Oncol 9(3): 390-396.
    • 5 Cao, C., et al. (2012). "Systematic review of trimodality therapy for patients with malignant pleural mesothelioma." Ann Cardiothorac Surg 1(4): 428-437.
    • 6 Cao, C., et al. (2011). "Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma." Ann Surg Oncol 18(10): 2973-2979.
    • 7 Ceresoli, G. L., et al. (2007). "Multidisciplinary treatment of malignant pleural mesothelioma." Oncologist 12(7): 850-863.
    • 8 Flores, R. M., et al. (2008). "Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients." J Thorac Cardiovasc Surg 135(3): 620-626, 626 e621-623.
    • 9 Flores, R. M., et al. (2008). "The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system." J Thorac Cardiovasc Surg 136(3): 605-610.
    • 10 Kao, S. C., et al. (2013). "Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma." Support Care Cancer 21(7): 1879-1884.
    • 11 Leuzzi, G., et al. (2015). "Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis." Ann Thorac Surg 100(3): 890-897.
    • 12 Mansfield, A. S., et al. (2014). "Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials." Lung Cancer 86(2): 133-136.
    • 13 Marshall, A. D., et al. (2015). "Survival from malignant mesothelioma: where are we now?" J R Coll Physicians Edinb 45(2): 123-126.
    • 14 Meyerhoff, R. R., et al. (2015). "Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database." J Surg Res 196(1): 23-32.
    • 15 Milano, M. T. and H. Zhang (2010). "Malignant pleural mesothelioma: a population-based study of survival." J Thorac Oncol 5(11): 1841-1848.
    • 16 Minatel, E., et al. (2014). "Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up." Lung Cancer 83(1): 78-82.
    • 17 Mineo, T. C. and V. Ambrogi (2012). "Malignant pleural mesothelioma: factors influencing the prognosis." Oncology (Williston Park) 26(12): 1164-1175.
    • 18 Neragi-Miandoab, S., et al. (2008). "Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma." Int J Surg 6(4): 293-297.
    • 19 Rice, D. C., et al. (2007). "Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma." Ann Thorac Surg 84(5): 1685-1692; discussion 1692-1683.
    • 20 Rosenzweig, K. E., et al. (2012). "Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma." Int J Radiat Oncol Biol Phys 83(4): 1278-1283.
    • 21 Rusch, V. W., et al. (2012). "Initial analysis of the international association for the study of lung cancer mesothelioma database." J Thorac Oncol 7(11): 1631-1639.
    • 22 Sugarbaker, D. J., et al. (2014). "Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients." Ann Surg 260(4): 577-580; discussion 580-572.
    • 23 Taioli, E., et al. (2015). "Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients." PLoS One 10(12): e0145039.
    • 24 Van Schil, P. E., et al. (2010). "Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial." Eur Respir J 36(6): 1362-1369.
    • 25 Vogelzang, N. J., et al. (2003). "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma." J Clin Oncol 21(14): 2636-2644.
    • 26 Weder, W., et al. (2007). "Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma." Ann Oncol 18(7): 1196-1202.
    • 27 Zhang, W., et al. (2015). "Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma." Ann Transl Med 3(13): 182.
    • About The Writer Photo of Dan Heil Dan Heil

      Dan is a contributing writer for The Mesothelioma + Asbestos Awareness Center. He hopes to help educate on everything related to a mesothelioma diagnosis and answer any questions patients or family members may have.